Results 171 to 180 of about 24,238 (294)

hnRNP A2B1 as a promising therapeutic target for radiomodulatory drug development: evidence from computational and experimental studies. [PDF]

open access: yesFront Pharmacol
Lubinets NS   +10 more
europepmc   +1 more source

A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Aberrant activation of type 2 ryanodine receptors (RyR2) causes lethal arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Developing drugs that suppress RyR2 hyperactivation may be key to novel arrhythmia treatments.
Nagomi Kurebayashi   +29 more
wiley   +1 more source

When help is harm. [PDF]

open access: yesSci Adv
Farris AD, Jupudi AA.
europepmc   +1 more source

MiR‐375 in CAFs‐Derived EVs Promotes HCC Progression via Regulating RASA1 and May Potentially Serve as a Biomarker for HCC

open access: yesCancer Science, EarlyView.
CAFs could transfer EVs miR‐375 into endothelial cells with a low level of RASA1 and further promote EC angiogenesis. Plasma EVs miR‐375 have the potential values as a novel diagnostic and prognostic biomarker for HCC. ABSTRACT Cancer‐associated fibroblasts (CAFs) in the tumor microenvironment play an important role in cancer initiation and progression
Wei Qin   +6 more
wiley   +1 more source

MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy

open access: yesCancer Science, EarlyView.
MTAP deletion creates a therapeutically actionable metabolic vulnerability through MTA accumulation and PRMT5 dependency. This review summarizes the biochemical basis of MTAP‐directed synthetic lethality, emerging PRMT5/MAT2A inhibitors, clinicogenomic features of MTAP‐deleted tumors, and future strategies for precision oncology.
Hiroaki Ikushima, Hidenori Kage
wiley   +1 more source

CRISPR-Cas Technology Turns <i>Chlamydomonas reinhardtii</i> into a Flagship for Algal Biotechnology. [PDF]

open access: yesMar Drugs
Antonacci A   +6 more
europepmc   +1 more source

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr‐Mutant Lung Cancer Mouse Model

open access: yesCancer Science, EarlyView.
Using an immunocompetent mouse model of Egfr Ex19del‐driven lung cancer, we found that osimertinib‐resistant tumors acquired Egfr V804F, the murine counterpart of human EGFR V802F. Afatinib, but not osimertinib, suppressed phosphorylation of EGFR and overcame V804F‐mediated resistance, providing a preclinical rationale for biomarker‐guided therapy ...
Takaaki Tanaka   +22 more
wiley   +1 more source

Tumor‐Derived Exosomal piR‐hsa‐28212 Promotes Lymphatic Metastasis in Breast Cancer

open access: yesCancer Science, EarlyView.
Breast cancer–derived exosomal piR‐hsa‐28212 promotes lymphangiogenesis and lymph node metastasis by activating VEGFC/VEGFR3 signaling. It stabilizes TBX1 mRNA in lymphatic endothelial cells and METTL3 protein in tumor cells, enhancing VEGFR3 expression and VEGFC secretion.
Yafen Wang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy